Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Saad, F.; Efstathiou, E.; Attard, G.; Flaig, T. W.; Franke, F.; Goodman, O.; Oudard, S.; Steuber, T.; Suzuki, H.; Pieczonka, C. M.; Parnis, F.; Wu, D.; Yeruva, K.; De Porre, P.; Brookman-May, S. D.; Li, S.; Li, J.; Mundle, S.; McCarthy, S. A.; Rathkopf, D. E.; for the ACIS Investigators |
| Abstract Title: | Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120603058 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.5037 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 5037 -- Source: Wos |
